Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

NCT05245344 is registered in ClinicalTrials.gov with Neuromed IRCCS as lead sponsor.

NCT NCT05245344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
Lead sponsor
Neuromed IRCCS
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2022
Completion date
October 31, 2023
Enrollment
154 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, neuromyelitis optica, relapsing-remitting multiple sclerosis (rrms)